Scartozzi, Mario
 Distribuzione geografica
Continente #
NA - Nord America 824
EU - Europa 249
AS - Asia 163
AF - Africa 61
SA - Sud America 1
Totale 1.298
Nazione #
US - Stati Uniti d'America 809
SE - Svezia 85
SG - Singapore 75
IT - Italia 60
CN - Cina 48
CI - Costa d'Avorio 40
GB - Regno Unito 24
AT - Austria 21
BG - Bulgaria 20
TR - Turchia 20
DE - Germania 19
CA - Canada 15
SN - Senegal 14
VN - Vietnam 14
NG - Nigeria 5
HK - Hong Kong 4
ES - Italia 3
FR - Francia 3
RO - Romania 3
BE - Belgio 2
CZ - Repubblica Ceca 2
EG - Egitto 2
FI - Finlandia 2
RU - Federazione Russa 2
AL - Albania 1
AR - Argentina 1
EE - Estonia 1
JP - Giappone 1
MY - Malesia 1
UA - Ucraina 1
Totale 1.298
Città #
Chandler 102
Fairfield 81
Woodbridge 64
Ashburn 53
Abidjan 40
Singapore 38
Houston 35
Wilmington 34
Santa Clara 32
Cambridge 31
Seattle 31
Boardman 30
New York 29
Princeton 24
Lawrence 21
Vienna 21
Florence 20
Sofia 20
Istanbul 17
Medford 16
Bremen 14
Dakar 14
Ann Arbor 13
Ottawa 13
London 11
Council Bluffs 10
Kent 9
San Diego 9
Dearborn 7
Des Moines 7
Dong Ket 6
Fuzhou 6
Serra 6
Lagos 5
Nanjing 5
Redwood City 5
Shanghai 5
Guangzhou 4
Hong Kong 4
Milan 4
Ogden 4
Quanzhou 4
Seacroft 4
Beijing 3
Bitonto 3
Frankfurt am Main 3
Hebei 3
Izmir 3
Lancaster 3
Murcia 3
Nanchang 3
Phoenix 3
Turin 3
Abbiategrasso 2
Brussels 2
Center 2
Changsha 2
Modugno 2
Norwalk 2
Pisa 2
Redmond 2
Washington 2
Bucharest 1
Cento 1
Chengdu 1
Duncan 1
Eagleville 1
Edmonton 1
Elk Grove Village 1
Fort Worth 1
Hefei 1
Jacksonville 1
Jiaxing 1
Kunming 1
Lappeenranta 1
Los Angeles 1
Ninh Binh 1
Pistoia 1
Shenyang 1
Taizhou 1
Tallinn 1
Tirana 1
Toronto 1
Verona 1
Wuhan 1
Totale 979
Nome #
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 123
Natural history of malignant bone disease in hepatocellular carcinoma: Final results of a multicenter bone metastasis survey 106
Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol 99
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies 84
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 83
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: A fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis 72
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 68
Cholangiocarcinoma: new perspectives for new horizons 59
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 54
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 50
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 49
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 44
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 43
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 43
Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: Results of the multicenter prospective INNOVATE study 42
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 42
Erratum to: Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy (The Oncologist, (2017), 22, 12, (1463-1469), 10.1634/theoncologist.2017-0158) 40
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 37
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 35
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 34
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer 33
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 24
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis 13
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 11
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 11
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 11
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 10
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 10
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 9
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 9
Totale 1.348
Categoria #
all - tutte 6.411
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.411


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020137 0 0 0 0 38 21 25 20 18 6 5 4
2020/202167 4 7 5 4 2 9 2 6 4 4 3 17
2021/2022186 3 8 4 1 11 50 3 11 5 21 21 48
2022/2023396 38 60 32 24 40 45 6 24 88 2 31 6
2023/2024173 14 15 23 4 20 24 15 14 7 1 14 22
2024/2025204 2 73 33 51 45 0 0 0 0 0 0 0
Totale 1.348